You are here

P&T January 2011

Features

Drug Class Review
Current Evidence and Future Directions
The question of whether the pleiotropic effects of combining an ARB with an ACE inhibitor would provide a greater vascular advantage over either class of agent alone has not been directly addressed in clinical trials to date.
Commentary
Pharmacy Systems Will Be Updated Slowly but Surely
Meeting Highlights
43rd Annual Meeting & Scientific Exposition